Intrauterine contraceptives: A review of uses, side effects, and candidates

Seminars in Reproductive Medicine

Volumn 28, Issue 2, 2010, Pages 118-125

  Shimoni, Noa'A ^a  

^a Department of Medicine   (United States)

Author keywords

Intrauterine device; Intrauterine system; LNG IUS; Mirena; ParaGard

Indexed keywords

AZITHROMYCIN; COPPER INTRAUTERINE DEVICE; DOXYCYCLINE; LEVONORGESTREL;

ADENOMYOSIS; BLEEDING; DRUG EFFICACY; ENDOMETRIOSIS; ESTROGEN THERAPY; HUMAN; IMMUNOCOMPROMISED PATIENT; INTRAUTERINE CONTRACEPTIVE DEVICE; MENORRHAGIA; NULLIPARA; PAIN; PELVIC INFLAMMATORY DISEASE; REVIEW; SEXUALLY TRANSMITTED DISEASE; UTERUS PERFORATION;

CONTRACEPTION, POSTCOITAL; DELAYED-ACTION PREPARATIONS; ENDOMETRIOSIS; FEMALE; HUMANS; INTRAUTERINE DEVICES; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MENORRHAGIA;

EID: 77950542021     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0030-1248136     Document Type: Review

References (49)

1. United Nations. World Contraceptive Use 2007. New York, NY United Nations Publications 2007
2. Duramed Pharmaceuticals. Prescribing Information ParaGard T380A. 2006
3. Bayer HealthCare Pharmaceuticals. Mirena Physician Prescribing Information. 2008
4. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 1999 181 (5 Pt 1) 1263-1269
5. Stanford J B., Mikolajczyk R T. Mechanisms of action of intrauterine devices: update and estimation of postfertilization effects. Am J Obstet Gynecol 2002 187 (6) 1699-1708
6. Lhteenmki P, Rauramo I, Backman T. The levonorgestrel intrauterine system in contraception. Steroids 2000 65 (10-11) 693-697
7. Barbosa I, Bakos O, Olsson S E., Odlind V, Johansson E D. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990 42 (1) 51-66
8. Bahamondes L, Hidalgo M, Petta C A., Diaz J, Espejo-Arce X, Monteiro-Dantas C. Enlarged ovarian follicles in users of a levonorgestrel- releasing intrauterine system and contraceptive implant. J Reprod Med 2003 48 (8) 637-640
9. United Nations Development Programme. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception 1997 56 (6) 341-352
10. Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol 2004 190 (1) 50-54
11. Peterson H B., Xia Z, Hughes J M., Wilcox L S., Tylor L R., Trussell J. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996 174 (4) 1161-1168, discussion 11681170
12. Trussell J, Lalla A M., Doan Q V., Reyes E, Pinto L, Gricar J. Cost effectiveness of contraceptives in the United States. Contraception 2009 79 (1) 5-14
13. Ellertson C, Trussell J, Stewart F, Koenig J, Raymond E G., Shochet T. Emergency contraception. Semin Reprod Med 2001 19 (4) 323-330
14. Milsom I, Andersson K, Jonasson K, Lindstedt G, Rybo G. The influence of the Gyne-T 380S IUD on menstrual blood loss and iron status. Contraception 1995 52 (3) 175-179
15. World Health Organization. The TCu380A, TCu220C, multiload 250 and nova T IUDs at 3, 5 and 7 years of useresults from three randomized multicentre trials. Contraception 1990 42 (2) 141-158
16. Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002 65 (2) 129-132 (Pubitemid 34258502)
17. Zhang J, Feldblum P J., Chi I C., Farr M G. Risk factors for copper T IUD expulsion: an epidemiologic analysis. Contraception 1992 46 (5) 427-433
18. Bahamondes L, Daz J, Marchi N M., Petta C A., Cristofoletti M L., Gomez G. Performance of copper intrauterine devices when inserted after an expulsion. Hum Reprod 1995 10 (11) 2917-2918
19. Harrison-Woolrych M, Ashton J, Coulter D. Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported? Contraception 2003 67 (1) 53-56
20. World Health Organization. Selected Practice Recommendations for Contraceptive Use [update]. Geneva, Switzerland World Health Organization 2004
21. Farley T MM, Rosenberg M J., Rowe P J., Chen J H., Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992 339 (8796) 785-788
22. Grimes D A., Schulz K F. Prophylactic antibiotics for intrauterine device insertion: a metaanalysis of the randomized controlled trials. Contraception 1999 60 (2) 57-63
23. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994 49 (1) 56-72
24. Pakarinen P, Toivonen J, Luukkainen T, Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years' follow-up. Contraception 2003 68 (1) 31-34
25. Anonymous. IUD insertion following termination of pregnancy: a clinical trial of the TCu 220C, Lippes loop D, and copper 7. Stud Fam Plann 1983 14 (4) 99-108
26. Drey E A., Reeves M F., Ogawa D D., Sokoloff A, Darney P D., Steinauer J E. Insertion of intrauterine contraceptives immediately following first- and second-trimester abortions. Contraception 2009 79 (5) 397-402
27. Goodman S, Hendlish S K., Benedict C, Reeves M F., Pera-Floyd M, Foster-Rosales A. Increasing intrauterine contraception use by reducing barriers to post-abortal and interval insertion. Contraception 2008 78 (2) 136-142
28. Grimes D, Schulz K, van Vliet H, Stanwood N. Immediate post-partum insertion of intrauterine devices: a Cochrane review. Hum Reprod 2002 17 (3) 549-554
29. elen S, Mry P, Sucak A, Aktulay A, Daniman N. Clinical outcomes of early postplacental insertion of intrauterine contraceptive devices. Contraception 2004 69 (4) 279-282
30. Erolu K, Akkuzu G, Vural G et al. Comparison of efficacy and complications of IUD insertion in immediate postplacental/early postpartum period with interval period: 1 year follow-up. Contraception 2006 74 (5) 376-381
31. Hayes J L., Cwiak C, Goedken P, Zieman M. A pilot clinical trial of ultrasound-guided postplacental insertion of a levonorgestrel intrauterine device. Contraception 2007 76 (4) 292-296
32. Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception 2007 75 (6, suppl) S8-S11
33. Sivin I, Stern J. Long-acting, more effective copper T IUDs: a summary of U.S. experience, 197075. Stud Fam Plann 1979 10 (10) 263-281
34. Veldhuis H M., Vos A G., Lagro-Janssen A L., Lagro-Janssen A LM. Complications of the intrauterine device in nulliparous and parous women. Eur J Gen Pract 2004 10 (3) 82-87
35. Deans E I., Grimes D A. Intrauterine devices for adolescents: a systematic review. Contraception 2009 79 (6) 418-423
36. Paterson H, Ashton J, Harrison-Woolrych M, Paterson H, Ashton J, Harrison-Woolrych M. A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents. Contraception 2009 79 (6) 433-438
37. Morrison C S., Sekadde-Kigondu C, Sinei S K., Weiner D H., Kwok C, Kokonya D. Is the intrauterine device appropriate contraception for HIV-1-infected women? BJOG 2001 108 (8) 784-790
38. Stringer E M., Kaseba C, Levy J et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007 197 (2) 141-148
39. Heikinheimo O, Lehtovirta P, Suni J, Paavonen J. The levonorgestrel- releasing intrauterine system (LNG-IUS) in HIV-infected womeneffects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod 2006 21 (11) 2857-2861
40. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991 164 (3) 879-883
41. Irvine G A., Campbell-Brown M B., Lumsden M A., Heikkila A, Walker J J., Cameron I T. Randomized comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998 105 (6) 592-598
42. Hurskainen R, Teperi J, Rissanen P et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004 291 (12) 1456-1463 (Pubitemid 38543736)
43. Andersson K, Mattsson L A., Rybo G, Stadberg E. Intrauterine release of levonorgestrela new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992 79 (6) 963-967
44. Boon J, Scholten P C., Oldenhave A, Heintz A P. Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT. Maturitas 2003 46 (1) 69-77
45. Raudaskoski T, Tapanainen J, Toms E et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002 109 (2) 136-144
46. Petta C A., Ferriani R A., Abrao M S. et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005 20 (7) 1993-1998
47. Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani P G. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 2003 80 (2) 305-309
48. Sheng J, Zhang W Y., Zhang J P., Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 2009 79 (3) 189-193
49. Lockhat F B., Emembolu J O., Konje J C., Lockhat F B., Emembolu J O., Konje J C. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod 2005 20 (3) 789-793